enGene’s (ENGN) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of enGene (NASDAQ:ENGN) in a research note released on Tuesday morning,Benzinga reports. The firm currently has a $25.00 target price on the stock.

Other research analysts have also recently issued research reports about the stock. JMP Securities restated a “market outperform” rating and issued a $18.00 target price on shares of enGene in a report on Monday, December 23rd. Citizens Jmp upgraded shares of enGene to a “strong-buy” rating in a research report on Monday, November 18th. Raymond James assumed coverage on shares of enGene in a research note on Wednesday, November 27th. They set an “outperform” rating and a $23.00 price objective for the company. UBS Group downgraded enGene from a “buy” rating to a “neutral” rating and reduced their price target for the company from $34.00 to $7.00 in a report on Friday, February 14th. Finally, Piper Sandler began coverage on enGene in a report on Tuesday, February 18th. They set an “overweight” rating and a $26.00 target price for the company. One equities research analyst has rated the stock with a hold rating, eight have assigned a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $25.22.

enGene Trading Down 1.7 %

NASDAQ ENGN opened at $5.15 on Tuesday. The company has a quick ratio of 16.87, a current ratio of 16.87 and a debt-to-equity ratio of 0.08. The business has a 50 day moving average price of $6.62 and a 200-day moving average price of $7.15. The company has a market cap of $262.53 million, a price-to-earnings ratio of -8.88 and a beta of -0.61. enGene has a 52 week low of $4.42 and a 52 week high of $18.40.

enGene (NASDAQ:ENGN) last issued its quarterly earnings results on Thursday, December 19th. The company reported ($0.34) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.06. As a group, equities analysts expect that enGene will post -1.56 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently made changes to their positions in the stock. Wolverine Asset Management LLC purchased a new position in shares of enGene in the third quarter valued at about $37,000. Vontobel Holding Ltd. bought a new stake in enGene during the 4th quarter valued at approximately $69,000. Jane Street Group LLC bought a new position in enGene in the 4th quarter worth approximately $93,000. Toronto Dominion Bank bought a new position in enGene in the 4th quarter worth approximately $97,000. Finally, Cubist Systematic Strategies LLC grew its holdings in enGene by 15.7% during the 4th quarter. Cubist Systematic Strategies LLC now owns 15,342 shares of the company’s stock valued at $102,000 after buying an additional 2,080 shares in the last quarter. 64.16% of the stock is currently owned by institutional investors.

About enGene

enGene Holdings Inc, through its subsidiary enGene, Inc, operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin.